A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort.
Central and Systemic Inflammation in Alzheimer's Disease
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
|4||Active, not recruiting||
Genetics of Mendelian Forms of Young Onset Alzheimer Disease
† Indicates status has not been verified in more than two years